Amneal Pharmaceuticals reported third quarter 2026 results that exceeded analyst estimates on both top and bottom lines, driven by significant growth in its high-value product portfolios. The company leveraged a 10% increase in total revenue to raise its full-year 2026 financial guidance for the third time this year, reflecting accelerating momentum in biosimilars and complex injectables.
Key Highlights
- Affordable Medicines revenue climbed 19% to $547 million, primarily fueled by the expansion of the biosimilars portfolio and new product launches including generic lanreotide.
- Specialty segment revenue increased 20% to $192 million, supported by strong performance from branded products such as CREXONT and the BREKIYA autoinjector.
- Adjusted EBITDA rose 30% year-over-year to $207 million, benefiting from favorable product mix and disciplined operating expense management.
- Full-year 2026 revenue guidance was raised to a range of $3.15 billion–$3.25 billion, with adjusted diluted EPS now expected between $1.04 and $1.08.